Stem definition | Drug id | CAS RN |
---|---|---|
serotonin and/or norepinephrine reuptake inhibitors, fluoxetine derivatives | 4806 | 508233-74-7 |
Dose | Unit | Route |
---|---|---|
10 | mg | O |
Property | Value | Reference |
---|---|---|
Vd (Volume of distribution) | 35.30 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 5.80 mL/min/kg | Lombardo F, Berellini G, Obach RS |
fu (Fraction unbound in plasma) | 0.02 % | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 72 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
Sept. 20, 2019 | PMDA | Takeda Pharmaceutical Company Limited | |
Sept. 30, 2013 | FDA | TAKEDA PHARMS USA | |
Dec. 18, 2013 | EMA |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Suicidal ideation | 512.50 | 17.42 | 271 | 16086 | 62150 | 63410515 |
Nausea | 357.51 | 17.42 | 717 | 15640 | 853754 | 62618911 |
Serotonin syndrome | 200.19 | 17.42 | 112 | 16245 | 28570 | 63444095 |
Suicide attempt | 184.73 | 17.42 | 141 | 16216 | 60777 | 63411888 |
No adverse event | 159.98 | 17.42 | 111 | 16246 | 41294 | 63431371 |
Pruritus | 146.59 | 17.42 | 301 | 16056 | 361152 | 63111513 |
Anxiety | 132.24 | 17.42 | 216 | 16141 | 217325 | 63255340 |
Reaction to excipient | 128.52 | 17.42 | 36 | 16321 | 1428 | 63471237 |
Irritability | 122.48 | 17.42 | 85 | 16272 | 31609 | 63441056 |
Sopor | 101.35 | 17.42 | 66 | 16291 | 22098 | 63450567 |
Somnolence | 98.59 | 17.42 | 170 | 16187 | 178515 | 63294150 |
Intentional overdose | 96.69 | 17.42 | 107 | 16250 | 74045 | 63398620 |
Feeling abnormal | 96.42 | 17.42 | 152 | 16205 | 148240 | 63324425 |
Mania | 90.91 | 17.42 | 50 | 16307 | 12317 | 63460348 |
Anger | 90.58 | 17.42 | 50 | 16307 | 12406 | 63460259 |
Tremor | 75.77 | 17.42 | 128 | 16229 | 132111 | 63340554 |
Nightmare | 75.36 | 17.42 | 52 | 16305 | 19142 | 63453523 |
Intentional self-injury | 74.60 | 17.42 | 58 | 16299 | 25629 | 63447036 |
Agitation | 74.07 | 17.42 | 84 | 16273 | 59673 | 63412992 |
Libido increased | 69.68 | 17.42 | 22 | 16335 | 1323 | 63471342 |
Decompression sickness | 63.02 | 17.42 | 12 | 16345 | 78 | 63472587 |
Depression | 62.77 | 17.42 | 149 | 16208 | 196343 | 63276322 |
Drug abuse | 62.60 | 17.42 | 85 | 16272 | 72433 | 63400232 |
Abnormal dreams | 62.47 | 17.42 | 37 | 16320 | 10479 | 63462186 |
Product administered to patient of inappropriate age | 60.63 | 17.42 | 25 | 16332 | 3243 | 63469422 |
Sedation | 59.39 | 17.42 | 61 | 16296 | 38748 | 63433917 |
Akathisia | 59.14 | 17.42 | 34 | 16323 | 9112 | 63463553 |
Wrong technique in product usage process | 58.30 | 17.42 | 76 | 16281 | 62264 | 63410401 |
Soft tissue injury | 57.44 | 17.42 | 20 | 16337 | 1632 | 63471033 |
Insomnia | 57.00 | 17.42 | 152 | 16205 | 215100 | 63257565 |
Sexual dysfunction | 56.84 | 17.42 | 26 | 16331 | 4333 | 63468332 |
Crying | 55.70 | 17.42 | 47 | 16310 | 23296 | 63449369 |
Hostility | 54.99 | 17.42 | 20 | 16337 | 1852 | 63470813 |
Urinary retention | 54.47 | 17.42 | 52 | 16305 | 30249 | 63442416 |
Post-traumatic neck syndrome | 53.00 | 17.42 | 20 | 16337 | 2054 | 63470611 |
Vomiting | 51.95 | 17.42 | 282 | 16075 | 559335 | 62913330 |
Sternal fracture | 51.38 | 17.42 | 20 | 16337 | 2234 | 63470431 |
Bradykinesia | 49.57 | 17.42 | 25 | 16332 | 5163 | 63467502 |
Electrocardiogram QT prolonged | 48.69 | 17.42 | 68 | 16289 | 59462 | 63413203 |
Myoglobinuria | 48.62 | 17.42 | 12 | 16345 | 288 | 63472377 |
Overdose | 47.76 | 17.42 | 97 | 16260 | 114981 | 63357684 |
Parkinsonism | 47.50 | 17.42 | 31 | 16326 | 10408 | 63462257 |
Weight increased | 47.16 | 17.42 | 161 | 16196 | 260631 | 63212034 |
Peripheral circulatory failure | 46.71 | 17.42 | 15 | 16342 | 953 | 63471712 |
Joint swelling | 45.42 | 17.42 | 14 | 16343 | 327652 | 63145013 |
Hallucination, auditory | 43.99 | 17.42 | 32 | 16325 | 12792 | 63459873 |
Product use in unapproved indication | 43.93 | 17.42 | 123 | 16234 | 178957 | 63293708 |
Drug interaction | 43.66 | 17.42 | 144 | 16213 | 228987 | 63243678 |
Drug intolerance | 43.11 | 17.42 | 13 | 16344 | 308648 | 63164017 |
Pneumonia | 42.94 | 17.42 | 33 | 16324 | 456734 | 63015931 |
Inappropriate antidiuretic hormone secretion | 42.91 | 17.42 | 34 | 16323 | 15428 | 63457237 |
Hyperhidrosis | 42.51 | 17.42 | 89 | 16268 | 107747 | 63364918 |
Hyponatraemia | 40.27 | 17.42 | 89 | 16268 | 111811 | 63360854 |
Rheumatoid arthritis | 38.64 | 17.42 | 9 | 16348 | 253810 | 63218855 |
Neuroglycopenia | 38.54 | 17.42 | 11 | 16346 | 467 | 63472198 |
Maternal exposure during pregnancy | 37.30 | 17.42 | 6 | 16351 | 220056 | 63252609 |
Infusion related reaction | 36.80 | 17.42 | 9 | 16348 | 245512 | 63227153 |
Multiple drug therapy | 36.10 | 17.42 | 18 | 16339 | 3628 | 63469037 |
Dizziness | 36.05 | 17.42 | 211 | 16146 | 429714 | 63042951 |
Muscle twitching | 35.81 | 17.42 | 34 | 16323 | 19634 | 63453031 |
Restlessness | 35.79 | 17.42 | 41 | 16316 | 29412 | 63443253 |
Glossodynia | 34.95 | 17.42 | 3 | 16354 | 178873 | 63293792 |
Systemic lupus erythematosus | 34.73 | 17.42 | 6 | 16351 | 208912 | 63263753 |
Hepatic infiltration eosinophilic | 34.57 | 17.42 | 6 | 16351 | 21 | 63472644 |
Swelling | 34.33 | 17.42 | 14 | 16343 | 275364 | 63197301 |
Personality disorder | 33.35 | 17.42 | 20 | 16337 | 5791 | 63466874 |
Psychomotor hyperactivity | 32.97 | 17.42 | 25 | 16332 | 10638 | 63462027 |
Arthropathy | 32.57 | 17.42 | 10 | 16347 | 234782 | 63237883 |
Muscle rigidity | 31.30 | 17.42 | 25 | 16332 | 11475 | 63461190 |
Completed suicide | 30.86 | 17.42 | 95 | 16262 | 145578 | 63327087 |
Stupor | 30.63 | 17.42 | 17 | 16340 | 4258 | 63468407 |
Pain | 30.55 | 17.42 | 94 | 16263 | 740534 | 62732131 |
Treatment failure | 30.40 | 17.42 | 7 | 16350 | 199036 | 63273629 |
Pregnancy | 29.99 | 17.42 | 42 | 16315 | 36794 | 63435871 |
Infection | 29.63 | 17.42 | 11 | 16346 | 229162 | 63243503 |
Middle insomnia | 29.22 | 17.42 | 25 | 16332 | 12618 | 63460047 |
Major depression | 27.48 | 17.42 | 20 | 16337 | 7998 | 63464667 |
Migraine | 27.32 | 17.42 | 73 | 16284 | 103273 | 63369392 |
Antipsychotic drug level above therapeutic | 26.44 | 17.42 | 10 | 16347 | 1033 | 63471632 |
Hyperaldosteronism | 26.00 | 17.42 | 7 | 16350 | 239 | 63472426 |
Dementia | 26.00 | 17.42 | 28 | 16329 | 18766 | 63453899 |
Energy increased | 25.55 | 17.42 | 13 | 16344 | 2734 | 63469931 |
Dyspnoea | 25.12 | 17.42 | 87 | 16270 | 661226 | 62811439 |
Concussion | 24.95 | 17.42 | 20 | 16337 | 9224 | 63463441 |
Dissociation | 24.81 | 17.42 | 13 | 16344 | 2906 | 63469759 |
Headache | 24.61 | 17.42 | 260 | 16097 | 632981 | 62839684 |
Drug screen false positive | 24.32 | 17.42 | 9 | 16348 | 875 | 63471790 |
Vertigo | 24.25 | 17.42 | 50 | 16307 | 59837 | 63412828 |
Contraindicated product administered | 24.13 | 17.42 | 13 | 16344 | 217635 | 63255030 |
Prescription form tampering | 24.02 | 17.42 | 8 | 16349 | 570 | 63472095 |
Hypersensitivity | 24.01 | 17.42 | 24 | 16333 | 292661 | 63180004 |
Body temperature increased | 23.96 | 17.42 | 38 | 16319 | 37154 | 63435511 |
Tachyphrenia | 23.77 | 17.42 | 10 | 16347 | 1364 | 63471301 |
Hallucination | 23.67 | 17.42 | 47 | 16310 | 54770 | 63417895 |
Mental disorder | 23.29 | 17.42 | 31 | 16326 | 25888 | 63446777 |
Anaemia | 23.01 | 17.42 | 25 | 16332 | 293405 | 63179260 |
Gastric polyps | 22.93 | 17.42 | 13 | 16344 | 3392 | 63469273 |
Restless legs syndrome | 22.85 | 17.42 | 26 | 16331 | 18505 | 63454160 |
Antipsychotic drug level increased | 22.82 | 17.42 | 13 | 16344 | 3422 | 63469243 |
Haemoglobin decreased | 22.44 | 17.42 | 5 | 16352 | 145480 | 63327185 |
Labelled drug-drug interaction issue | 22.40 | 17.42 | 9 | 16348 | 1092 | 63471573 |
Product name confusion | 22.36 | 17.42 | 5 | 16352 | 77 | 63472588 |
Miosis | 22.21 | 17.42 | 17 | 16340 | 7336 | 63465329 |
Tardive dyskinesia | 22.11 | 17.42 | 18 | 16339 | 8484 | 63464181 |
Drug hypersensitivity | 21.68 | 17.42 | 29 | 16328 | 310658 | 63162007 |
Lymphocytic hypophysitis | 21.61 | 17.42 | 6 | 16351 | 230 | 63472435 |
Drug titration error | 21.26 | 17.42 | 8 | 16349 | 815 | 63471850 |
General physical health deterioration | 20.94 | 17.42 | 13 | 16344 | 201389 | 63271276 |
Memory impairment | 20.24 | 17.42 | 66 | 16291 | 104192 | 63368473 |
Self-injurious ideation | 20.23 | 17.42 | 11 | 16346 | 2648 | 63470017 |
Dysgeusia | 20.10 | 17.42 | 40 | 16317 | 46670 | 63425995 |
Thrombocytopenia | 19.96 | 17.42 | 7 | 16350 | 151150 | 63321515 |
Polydipsia | 19.77 | 17.42 | 12 | 16345 | 3552 | 63469113 |
Bacterial toxaemia | 19.71 | 17.42 | 3 | 16354 | 3 | 63472662 |
Poor quality sleep | 19.71 | 17.42 | 25 | 16332 | 19910 | 63452755 |
Death | 19.63 | 17.42 | 42 | 16315 | 374339 | 63098326 |
Aggression | 19.44 | 17.42 | 27 | 16330 | 23471 | 63449194 |
Panic attack | 18.98 | 17.42 | 26 | 16331 | 22305 | 63450360 |
Mydriasis | 18.66 | 17.42 | 19 | 16338 | 11937 | 63460728 |
Cor pulmonale acute | 18.42 | 17.42 | 6 | 16351 | 399 | 63472266 |
Withdrawal syndrome | 18.09 | 17.42 | 24 | 16333 | 19973 | 63452692 |
Initial insomnia | 18.08 | 17.42 | 14 | 16343 | 6143 | 63466522 |
Acute kidney injury | 17.96 | 17.42 | 25 | 16332 | 263390 | 63209275 |
Constipation | 17.89 | 17.42 | 109 | 16248 | 224834 | 63247831 |
Hypomania | 17.74 | 17.42 | 14 | 16343 | 6316 | 63466349 |
Lower respiratory tract infection | 17.69 | 17.42 | 6 | 16351 | 132301 | 63340364 |
Contraindicated product prescribed | 17.58 | 17.42 | 8 | 16349 | 1317 | 63471348 |
Libido decreased | 17.45 | 17.42 | 10 | 16347 | 2662 | 63470003 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Suicidal ideation | 339.15 | 25.57 | 158 | 6069 | 40230 | 34910474 |
Completed suicide | 178.39 | 25.57 | 144 | 6083 | 98024 | 34852680 |
Nausea | 101.11 | 25.57 | 200 | 6027 | 339708 | 34610996 |
Sexual dysfunction | 90.06 | 25.57 | 36 | 6191 | 6267 | 34944437 |
Suicide attempt | 89.64 | 25.57 | 66 | 6161 | 39050 | 34911654 |
Erectile dysfunction | 81.75 | 25.57 | 49 | 6178 | 20588 | 34930116 |
Dystonic tremor | 80.32 | 25.57 | 16 | 6211 | 203 | 34950501 |
Anxiety | 72.81 | 25.57 | 89 | 6138 | 99339 | 34851365 |
Intentional overdose | 72.63 | 25.57 | 61 | 6166 | 43613 | 34907091 |
Intentional self-injury | 52.71 | 25.57 | 32 | 6195 | 13739 | 34936965 |
Dissociation | 52.22 | 25.57 | 17 | 6210 | 1641 | 34949063 |
Product use in unapproved indication | 51.20 | 25.57 | 82 | 6145 | 117417 | 34833287 |
Mania | 49.50 | 25.57 | 27 | 6200 | 9484 | 34941220 |
Urinary retention | 46.97 | 25.57 | 44 | 6183 | 36244 | 34914460 |
Depressed mood | 45.12 | 25.57 | 33 | 6194 | 19284 | 34931420 |
Feeling abnormal | 43.63 | 25.57 | 55 | 6172 | 63180 | 34887524 |
Serotonin syndrome | 41.97 | 25.57 | 32 | 6195 | 19901 | 34930803 |
Drug ineffective | 41.11 | 25.57 | 175 | 6052 | 456576 | 34494128 |
No adverse event | 38.02 | 25.57 | 32 | 6195 | 22895 | 34927809 |
Product administered to patient of inappropriate age | 34.23 | 25.57 | 15 | 6212 | 3276 | 34947428 |
Irritability | 33.99 | 25.57 | 31 | 6196 | 24659 | 34926045 |
Sopor | 33.58 | 25.57 | 23 | 6204 | 12113 | 34938591 |
Agitation | 33.50 | 25.57 | 46 | 6181 | 57353 | 34893351 |
Disturbance in attention | 32.68 | 25.57 | 31 | 6196 | 25914 | 34924790 |
Vomiting | 32.25 | 25.57 | 107 | 6120 | 247514 | 34703190 |
Arterial disorder | 32.05 | 25.57 | 11 | 6216 | 1248 | 34949456 |
Anorgasmia | 31.98 | 25.57 | 10 | 6217 | 847 | 34949857 |
Anger | 31.65 | 25.57 | 22 | 6205 | 11862 | 34938842 |
Tremor | 31.06 | 25.57 | 54 | 6173 | 82533 | 34868171 |
Abulia | 31.01 | 25.57 | 9 | 6218 | 591 | 34950113 |
Thinking abnormal | 30.76 | 25.57 | 17 | 6210 | 6120 | 34944584 |
Feeling of despair | 30.69 | 25.57 | 10 | 6217 | 967 | 34949737 |
Restlessness | 29.37 | 25.57 | 29 | 6198 | 25453 | 34925251 |
Prescribed overdose | 29.04 | 25.57 | 20 | 6207 | 10627 | 34940077 |
Tardive dyskinesia | 28.92 | 25.57 | 16 | 6211 | 5774 | 34944930 |
Reaction to excipient | 27.84 | 25.57 | 8 | 6219 | 507 | 34950197 |
Insomnia | 26.88 | 25.57 | 58 | 6169 | 103849 | 34846855 |
Akathisia | 26.38 | 25.57 | 17 | 6210 | 8092 | 34942612 |
Depression | 26.04 | 25.57 | 55 | 6172 | 97043 | 34853661 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Suicidal ideation | 598.71 | 17.83 | 306 | 17398 | 76034 | 79650650 |
Nausea | 237.49 | 17.83 | 598 | 17106 | 956598 | 78770086 |
Suicide attempt | 233.66 | 17.83 | 173 | 17531 | 82759 | 79643925 |
Serotonin syndrome | 201.13 | 17.83 | 125 | 17579 | 44902 | 79681782 |
Anxiety | 147.26 | 17.83 | 225 | 17479 | 248287 | 79478397 |
Intentional overdose | 144.48 | 17.83 | 146 | 17558 | 105814 | 79620870 |
Sopor | 140.74 | 17.83 | 89 | 17615 | 32921 | 79693763 |
Completed suicide | 139.28 | 17.83 | 218 | 17486 | 245549 | 79481135 |
Irritability | 118.39 | 17.83 | 87 | 17617 | 41057 | 79685627 |
Intentional self-injury | 108.11 | 17.83 | 75 | 17629 | 32344 | 79694340 |
Product administered to patient of inappropriate age | 93.55 | 17.83 | 38 | 17666 | 5515 | 79721169 |
Urinary retention | 88.26 | 17.83 | 84 | 17620 | 56546 | 79670138 |
Tremor | 85.49 | 17.83 | 143 | 17561 | 169940 | 79556744 |
Pruritus | 83.11 | 17.83 | 233 | 17471 | 394415 | 79332269 |
Feeling abnormal | 80.20 | 17.83 | 134 | 17570 | 159065 | 79567619 |
Mania | 79.73 | 17.83 | 50 | 17654 | 18210 | 79708474 |
Sexual dysfunction | 78.22 | 17.83 | 37 | 17667 | 7726 | 79718958 |
Dystonic tremor | 76.80 | 17.83 | 16 | 17688 | 203 | 79726481 |
Product use in unapproved indication | 73.77 | 17.83 | 168 | 17536 | 250191 | 79476493 |
Sedation | 69.73 | 17.83 | 71 | 17633 | 51824 | 79674860 |
Depression | 67.80 | 17.83 | 149 | 17555 | 216641 | 79510043 |
Somnolence | 67.79 | 17.83 | 158 | 17546 | 238823 | 79487861 |
Anger | 67.50 | 17.83 | 44 | 17660 | 17118 | 79709566 |
Agitation | 67.13 | 17.83 | 96 | 17608 | 99619 | 79627065 |
Libido increased | 64.31 | 17.83 | 22 | 17682 | 1979 | 79724705 |
Decompression sickness | 64.28 | 17.83 | 12 | 17692 | 82 | 79726602 |
Nightmare | 64.01 | 17.83 | 50 | 17654 | 25811 | 79700873 |
No adverse event | 63.39 | 17.83 | 58 | 17646 | 37134 | 79689550 |
Dissociation | 59.22 | 17.83 | 25 | 17679 | 3996 | 79722688 |
Soft tissue injury | 58.88 | 17.83 | 20 | 17684 | 1761 | 79724923 |
Restlessness | 57.77 | 17.83 | 61 | 17643 | 46431 | 79680253 |
Insomnia | 56.75 | 17.83 | 150 | 17554 | 245020 | 79481664 |
Post-traumatic neck syndrome | 55.71 | 17.83 | 20 | 17684 | 2074 | 79724610 |
Akathisia | 54.62 | 17.83 | 35 | 17669 | 13224 | 79713460 |
Drug abuse | 54.48 | 17.83 | 115 | 17589 | 162576 | 79564108 |
Erectile dysfunction | 53.80 | 17.83 | 36 | 17668 | 14628 | 79712056 |
Hostility | 53.79 | 17.83 | 20 | 17684 | 2290 | 79724394 |
Inappropriate antidiuretic hormone secretion | 52.76 | 17.83 | 45 | 17659 | 26268 | 79700416 |
Sternal fracture | 52.02 | 17.83 | 20 | 17684 | 2510 | 79724174 |
Drug interaction | 51.40 | 17.83 | 205 | 17499 | 414978 | 79311706 |
Bradykinesia | 50.87 | 17.83 | 28 | 17676 | 8015 | 79718669 |
Hyperhidrosis | 50.62 | 17.83 | 107 | 17597 | 151385 | 79575299 |
Electrocardiogram QT prolonged | 49.43 | 17.83 | 79 | 17625 | 90307 | 79636377 |
Peripheral circulatory failure | 46.41 | 17.83 | 15 | 17689 | 1131 | 79725553 |
Hyponatraemia | 44.41 | 17.83 | 112 | 17592 | 177736 | 79548948 |
Abnormal dreams | 44.25 | 17.83 | 29 | 17675 | 11383 | 79715301 |
Pneumonia | 44.16 | 17.83 | 49 | 17655 | 660197 | 79066487 |
Vomiting | 44.00 | 17.83 | 275 | 17429 | 665553 | 79061131 |
Personality disorder | 43.35 | 17.83 | 23 | 17681 | 6123 | 79720561 |
Crying | 41.35 | 17.83 | 37 | 17667 | 23006 | 79703678 |
Antipsychotic drug level increased | 41.19 | 17.83 | 22 | 17682 | 5935 | 79720749 |
Hallucination, auditory | 40.69 | 17.83 | 35 | 17669 | 20658 | 79706026 |
Dizziness | 40.25 | 17.83 | 226 | 17478 | 526215 | 79200469 |
Neuroglycopenia | 40.03 | 17.83 | 11 | 17693 | 473 | 79726211 |
Tardive dyskinesia | 38.89 | 17.83 | 26 | 17678 | 10545 | 79716139 |
Weight increased | 37.56 | 17.83 | 141 | 17563 | 277245 | 79449439 |
Multiple drug therapy | 36.73 | 17.83 | 18 | 17686 | 4060 | 79722624 |
Parkinsonism | 36.64 | 17.83 | 30 | 17674 | 16554 | 79710130 |
Labelled drug-drug interaction issue | 35.73 | 17.83 | 13 | 17691 | 1400 | 79725284 |
Acute kidney injury | 35.30 | 17.83 | 38 | 17666 | 519366 | 79207318 |
Myoglobinuria | 34.98 | 17.83 | 12 | 17692 | 1088 | 79725596 |
Drug intolerance | 34.77 | 17.83 | 8 | 17696 | 264111 | 79462573 |
Dyspnoea | 34.71 | 17.83 | 88 | 17616 | 856937 | 78869747 |
Disturbance in attention | 34.30 | 17.83 | 49 | 17655 | 50752 | 79675932 |
Wrong technique in product usage process | 34.28 | 17.83 | 60 | 17644 | 73815 | 79652869 |
Underdose | 33.42 | 17.83 | 39 | 17665 | 33112 | 79693572 |
Overdose | 33.15 | 17.83 | 103 | 17601 | 184103 | 79542581 |
Major depression | 32.83 | 17.83 | 22 | 17682 | 8958 | 79717726 |
Mental disorder | 31.85 | 17.83 | 37 | 17667 | 31265 | 79695419 |
Migraine | 31.79 | 17.83 | 64 | 17640 | 87429 | 79639255 |
Haemoglobin decreased | 30.73 | 17.83 | 6 | 17698 | 222113 | 79504571 |
Vertigo | 30.62 | 17.83 | 55 | 17649 | 69027 | 79657657 |
Panic attack | 30.48 | 17.83 | 32 | 17672 | 24184 | 79702500 |
Febrile neutropenia | 30.40 | 17.83 | 7 | 17697 | 230992 | 79495692 |
Psychomotor hyperactivity | 30.12 | 17.83 | 27 | 17677 | 16822 | 79709862 |
Anorgasmia | 29.72 | 17.83 | 11 | 17693 | 1243 | 79725441 |
Libido decreased | 29.52 | 17.83 | 17 | 17687 | 5304 | 79721380 |
Concussion | 29.38 | 17.83 | 21 | 17683 | 9482 | 79717202 |
Anaemia | 28.65 | 17.83 | 34 | 17670 | 444981 | 79281703 |
Poor quality sleep | 28.55 | 17.83 | 30 | 17674 | 22692 | 79703992 |
Infusion related reaction | 28.33 | 17.83 | 8 | 17696 | 230229 | 79496455 |
Headache | 27.64 | 17.83 | 243 | 17461 | 653529 | 79073155 |
Joint swelling | 27.37 | 17.83 | 15 | 17689 | 288631 | 79438053 |
Depressed mood | 27.35 | 17.83 | 43 | 17661 | 48437 | 79678247 |
Dystonia | 26.44 | 17.83 | 28 | 17676 | 21371 | 79705313 |
Muscle twitching | 26.42 | 17.83 | 30 | 17674 | 24734 | 79701950 |
Bipolar disorder | 26.08 | 17.83 | 18 | 17686 | 7689 | 79718995 |
Stupor | 25.52 | 17.83 | 17 | 17687 | 6855 | 79719829 |
Infection | 25.28 | 17.83 | 11 | 17693 | 241701 | 79484983 |
Arterial disorder | 24.81 | 17.83 | 11 | 17693 | 1979 | 79724705 |
Death | 24.60 | 17.83 | 56 | 17648 | 566458 | 79160226 |
Muscle rigidity | 24.53 | 17.83 | 26 | 17678 | 19856 | 79706828 |
Abulia | 24.37 | 17.83 | 9 | 17695 | 1011 | 79725673 |
Tachyphrenia | 24.34 | 17.83 | 11 | 17693 | 2069 | 79724615 |
Prescription form tampering | 23.80 | 17.83 | 7 | 17697 | 385 | 79726299 |
Gastric polyps | 23.57 | 17.83 | 13 | 17691 | 3734 | 79722950 |
Hallucination | 23.50 | 17.83 | 56 | 17648 | 85689 | 79640995 |
Middle insomnia | 23.44 | 17.83 | 23 | 17681 | 16046 | 79710638 |
Hyperaldosteronism | 22.70 | 17.83 | 7 | 17697 | 453 | 79726231 |
Drug hypersensitivity | 22.44 | 17.83 | 20 | 17684 | 298896 | 79427788 |
Arthropathy | 22.07 | 17.83 | 6 | 17698 | 177105 | 79549579 |
Body temperature increased | 21.81 | 17.83 | 37 | 17667 | 44383 | 79682301 |
Disease progression | 21.60 | 17.83 | 7 | 17697 | 184355 | 79542329 |
Sepsis | 21.48 | 17.83 | 17 | 17687 | 269411 | 79457273 |
Activation syndrome | 21.38 | 17.83 | 6 | 17698 | 279 | 79726405 |
Antipsychotic drug level above therapeutic | 21.22 | 17.83 | 10 | 17694 | 2070 | 79724614 |
Lymphocytic hypophysitis | 21.20 | 17.83 | 7 | 17697 | 565 | 79726119 |
Rheumatoid arthritis | 21.00 | 17.83 | 10 | 17694 | 208460 | 79518224 |
Dysgeusia | 20.97 | 17.83 | 42 | 17662 | 57135 | 79669549 |
Swelling | 20.92 | 17.83 | 11 | 17693 | 216700 | 79509984 |
Hypersensitivity | 20.34 | 17.83 | 17 | 17687 | 262222 | 79464462 |
Stomatitis | 20.22 | 17.83 | 4 | 17700 | 146753 | 79579931 |
General physical health deterioration | 19.96 | 17.83 | 19 | 17685 | 275219 | 79451465 |
Mydriasis | 19.89 | 17.83 | 22 | 17682 | 17621 | 79709063 |
Drug titration error | 19.73 | 17.83 | 8 | 17696 | 1154 | 79725530 |
Energy increased | 19.59 | 17.83 | 11 | 17693 | 3271 | 79723413 |
Thinking abnormal | 19.50 | 17.83 | 19 | 17685 | 13142 | 79713542 |
Restless legs syndrome | 19.20 | 17.83 | 23 | 17681 | 20069 | 79706615 |
Dissociative disorder | 18.72 | 17.83 | 7 | 17697 | 814 | 79725870 |
Self-injurious ideation | 18.54 | 17.83 | 11 | 17693 | 3627 | 79723057 |
Renal impairment | 18.47 | 17.83 | 6 | 17698 | 157777 | 79568907 |
Initial insomnia | 18.44 | 17.83 | 14 | 17690 | 6924 | 79719760 |
Feeling of despair | 18.33 | 17.83 | 10 | 17694 | 2811 | 79723873 |
Negative thoughts | 18.30 | 17.83 | 8 | 17696 | 1391 | 79725293 |
Feeling jittery | 18.03 | 17.83 | 18 | 17686 | 12823 | 79713861 |
Blood creatinine increased | 17.97 | 17.83 | 6 | 17698 | 155051 | 79571633 |
Apathy | 17.87 | 17.83 | 18 | 17686 | 12959 | 79713725 |
Memory impairment | 17.84 | 17.83 | 60 | 17644 | 111674 | 79615010 |
None
Source | Code | Description |
---|---|---|
ATC | N06AX26 | NERVOUS SYSTEM PSYCHOANALEPTICS ANTIDEPRESSANTS Other antidepressants |
MeSH PA | D014151 | Anti-Anxiety Agents |
MeSH PA | D000928 | Antidepressive Agents |
MeSH PA | D002491 | Central Nervous System Agents |
MeSH PA | D002492 | Central Nervous System Depressants |
MeSH PA | D049990 | Membrane Transport Modulators |
MeSH PA | D018377 | Neurotransmitter Agents |
MeSH PA | D014179 | Neurotransmitter Uptake Inhibitors |
MeSH PA | D011619 | Psychotropic Drugs |
MeSH PA | D017367 | Selective Serotonin Reuptake Inhibitors |
MeSH PA | D058825 | Serotonin 5-HT1 Receptor Agonists |
MeSH PA | D058831 | Serotonin 5-HT3 Receptor Antagonists |
MeSH PA | D018490 | Serotonin Agents |
MeSH PA | D012702 | Serotonin Antagonists |
MeSH PA | D017366 | Serotonin Receptor Agonists |
MeSH PA | D014149 | Tranquilizing Agents |
CHEBI has role | CHEBI:35469 | antidepressants |
CHEBI has role | CHEBI:35474 | anti-anxiety agents |
CHEBI has role | CHEBI:35941 | serotonin agonists |
CHEBI has role | CHEBI:48279 | serotonin antagonists |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Major depressive disorder | indication | 370143000 | |
Monoamine oxidase inhibitors | contraindication |
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 9.02 | Basic |
pKa2 | 1.85 | Basic |
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
---|---|---|---|---|---|---|---|---|---|---|
EQ 10MG BASE | TRINTELLIX | TAKEDA PHARMS USA | N204447 | Sept. 30, 2013 | RX | TABLET | ORAL | 7144884 | June 17, 2026 | METHOD OF TREATING AN AFFECTIVE DISORDER SUCH AS DEPRESSION |
EQ 15MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TRINTELLIX | TAKEDA PHARMS USA | N204447 | Sept. 30, 2013 | DISCN | TABLET | ORAL | 7144884 | June 17, 2026 | METHOD OF TREATING AN AFFECTIVE DISORDER SUCH AS DEPRESSION |
EQ 20MG BASE | TRINTELLIX | TAKEDA PHARMS USA | N204447 | Sept. 30, 2013 | RX | TABLET | ORAL | 7144884 | June 17, 2026 | METHOD OF TREATING AN AFFECTIVE DISORDER SUCH AS DEPRESSION |
EQ 5MG BASE | TRINTELLIX | TAKEDA PHARMS USA | N204447 | Sept. 30, 2013 | RX | TABLET | ORAL | 7144884 | June 17, 2026 | METHOD OF TREATING AN AFFECTIVE DISORDER SUCH AS DEPRESSION |
EQ 10MG BASE | TRINTELLIX | TAKEDA PHARMS USA | N204447 | Sept. 30, 2013 | RX | TABLET | ORAL | 11458134 | June 15, 2027 | USE OF TRINTELLIX FOR THE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD) IN ADULTS |
EQ 10MG BASE | TRINTELLIX | TAKEDA PHARMS USA | N204447 | Sept. 30, 2013 | RX | TABLET | ORAL | 8969355 | June 15, 2027 | METHOD OF TREATING DEPRESSION OR MAJOR DEPRESSIVE DISORDER |
EQ 10MG BASE | TRINTELLIX | TAKEDA PHARMS USA | N204447 | Sept. 30, 2013 | RX | TABLET | ORAL | 9125908 | June 15, 2027 | USE IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER TO IMPROVE PROCESSING SPEED, AN ASPECT OF COGNITIVE FUNCTION |
EQ 10MG BASE | TRINTELLIX | TAKEDA PHARMS USA | N204447 | Sept. 30, 2013 | RX | TABLET | ORAL | 9125909 | June 15, 2027 | USE IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER TO IMPROVE PROCESSING SPEED, AN ASPECT OF COGNITIVE FUNCTION |
EQ 10MG BASE | TRINTELLIX | TAKEDA PHARMS USA | N204447 | Sept. 30, 2013 | RX | TABLET | ORAL | 9125910 | June 15, 2027 | USE IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER TO IMPROVE PROCESSING SPEED, AN ASPECT OF COGNITIVE FUNCTION |
EQ 10MG BASE | TRINTELLIX | TAKEDA PHARMS USA | N204447 | Sept. 30, 2013 | RX | TABLET | ORAL | 9227946 | June 15, 2027 | METHOD OF TREATING DEPRESSION OR MAJOR DEPRESSIVE DISORDER |
EQ 10MG BASE | TRINTELLIX | TAKEDA PHARMS USA | N204447 | Sept. 30, 2013 | RX | TABLET | ORAL | 9861630 | June 15, 2027 | METHOD OF TREATING DEPRESSION OR MAJOR DEPRESSIVE DISORDER |
EQ 15MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TRINTELLIX | TAKEDA PHARMS USA | N204447 | Sept. 30, 2013 | DISCN | TABLET | ORAL | 11458134 | June 15, 2027 | USE OF TRINTELLIX FOR THE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD) IN ADULTS |
EQ 15MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TRINTELLIX | TAKEDA PHARMS USA | N204447 | Sept. 30, 2013 | DISCN | TABLET | ORAL | 8969355 | June 15, 2027 | METHOD OF TREATING DEPRESSION OR MAJOR DEPRESSIVE DISORDER |
EQ 15MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TRINTELLIX | TAKEDA PHARMS USA | N204447 | Sept. 30, 2013 | DISCN | TABLET | ORAL | 9125908 | June 15, 2027 | USE IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER TO IMPROVE PROCESSING SPEED, AN ASPECT OF COGNITIVE FUNCTION |
EQ 15MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TRINTELLIX | TAKEDA PHARMS USA | N204447 | Sept. 30, 2013 | DISCN | TABLET | ORAL | 9125909 | June 15, 2027 | USE IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER TO IMPROVE PROCESSING SPEED, AN ASPECT OF COGNITIVE FUNCTION |
EQ 15MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TRINTELLIX | TAKEDA PHARMS USA | N204447 | Sept. 30, 2013 | DISCN | TABLET | ORAL | 9125910 | June 15, 2027 | USE IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER TO IMPROVE PROCESSING SPEED, AN ASPECT OF COGNITIVE FUNCTION |
EQ 15MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TRINTELLIX | TAKEDA PHARMS USA | N204447 | Sept. 30, 2013 | DISCN | TABLET | ORAL | 9227946 | June 15, 2027 | METHOD OF TREATING DEPRESSION OR MAJOR DEPRESSIVE DISORDER |
EQ 15MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TRINTELLIX | TAKEDA PHARMS USA | N204447 | Sept. 30, 2013 | DISCN | TABLET | ORAL | 9861630 | June 15, 2027 | METHOD OF TREATING DEPRESSION OR MAJOR DEPRESSIVE DISORDER |
EQ 20MG BASE | TRINTELLIX | TAKEDA PHARMS USA | N204447 | Sept. 30, 2013 | RX | TABLET | ORAL | 11458134 | June 15, 2027 | USE OF TRINTELLIX FOR THE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD) IN ADULTS |
EQ 20MG BASE | TRINTELLIX | TAKEDA PHARMS USA | N204447 | Sept. 30, 2013 | RX | TABLET | ORAL | 8969355 | June 15, 2027 | METHOD OF TREATING DEPRESSION OR MAJOR DEPRESSIVE DISORDER |
EQ 20MG BASE | TRINTELLIX | TAKEDA PHARMS USA | N204447 | Sept. 30, 2013 | RX | TABLET | ORAL | 9125908 | June 15, 2027 | USE IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER TO IMPROVE PROCESSING SPEED, AN ASPECT OF COGNITIVE FUNCTION |
EQ 20MG BASE | TRINTELLIX | TAKEDA PHARMS USA | N204447 | Sept. 30, 2013 | RX | TABLET | ORAL | 9125909 | June 15, 2027 | USE IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER TO IMPROVE PROCESSING SPEED, AN ASPECT OF COGNITIVE FUNCTION |
EQ 20MG BASE | TRINTELLIX | TAKEDA PHARMS USA | N204447 | Sept. 30, 2013 | RX | TABLET | ORAL | 9125910 | June 15, 2027 | USE IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER TO IMPROVE PROCESSING SPEED, AN ASPECT OF COGNITIVE FUNCTION |
EQ 20MG BASE | TRINTELLIX | TAKEDA PHARMS USA | N204447 | Sept. 30, 2013 | RX | TABLET | ORAL | 9227946 | June 15, 2027 | METHOD OF TREATING DEPRESSION OR MAJOR DEPRESSIVE DISORDER |
EQ 20MG BASE | TRINTELLIX | TAKEDA PHARMS USA | N204447 | Sept. 30, 2013 | RX | TABLET | ORAL | 9861630 | June 15, 2027 | METHOD OF TREATING DEPRESSION OR MAJOR DEPRESSIVE DISORDER |
EQ 5MG BASE | TRINTELLIX | TAKEDA PHARMS USA | N204447 | Sept. 30, 2013 | RX | TABLET | ORAL | 11458134 | June 15, 2027 | USE OF TRINTELLIX FOR THE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD) IN ADULTS |
EQ 5MG BASE | TRINTELLIX | TAKEDA PHARMS USA | N204447 | Sept. 30, 2013 | RX | TABLET | ORAL | 8969355 | June 15, 2027 | METHOD OF TREATING DEPRESSION OR MAJOR DEPRESSIVE DISORDER |
EQ 5MG BASE | TRINTELLIX | TAKEDA PHARMS USA | N204447 | Sept. 30, 2013 | RX | TABLET | ORAL | 9125908 | June 15, 2027 | USE IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER TO IMPROVE PROCESSING SPEED, AN ASPECT OF COGNITIVE FUNCTION |
EQ 5MG BASE | TRINTELLIX | TAKEDA PHARMS USA | N204447 | Sept. 30, 2013 | RX | TABLET | ORAL | 9125909 | June 15, 2027 | USE IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER TO IMPROVE PROCESSING SPEED, AN ASPECT OF COGNITIVE FUNCTION |
EQ 5MG BASE | TRINTELLIX | TAKEDA PHARMS USA | N204447 | Sept. 30, 2013 | RX | TABLET | ORAL | 9125910 | June 15, 2027 | USE IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER TO IMPROVE PROCESSING SPEED, AN ASPECT OF COGNITIVE FUNCTION |
EQ 5MG BASE | TRINTELLIX | TAKEDA PHARMS USA | N204447 | Sept. 30, 2013 | RX | TABLET | ORAL | 9227946 | June 15, 2027 | METHOD OF TREATING DEPRESSION OR MAJOR DEPRESSIVE DISORDER |
EQ 5MG BASE | TRINTELLIX | TAKEDA PHARMS USA | N204447 | Sept. 30, 2013 | RX | TABLET | ORAL | 9861630 | June 15, 2027 | METHOD OF TREATING DEPRESSION OR MAJOR DEPRESSIVE DISORDER |
EQ 10MG BASE | TRINTELLIX | TAKEDA PHARMS USA | N204447 | Sept. 30, 2013 | RX | TABLET | ORAL | 9278096 | March 21, 2032 | USE IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER TO IMPROVE TREATMENT EMERGENT SEXUAL DYSFUNCTION (TESD) INDUCED BY PRIOR SEROTONIN REUPTAKE INHIBITOR TREATMENT |
EQ 15MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TRINTELLIX | TAKEDA PHARMS USA | N204447 | Sept. 30, 2013 | DISCN | TABLET | ORAL | 9278096 | March 21, 2032 | USE IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER TO IMPROVE TREATMENT EMERGENT SEXUAL DYSFUNCTION (TESD) INDUCED BY PRIOR SEROTONIN REUPTAKE INHIBITOR TREATMENT |
EQ 20MG BASE | TRINTELLIX | TAKEDA PHARMS USA | N204447 | Sept. 30, 2013 | RX | TABLET | ORAL | 9278096 | March 21, 2032 | USE IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER TO IMPROVE TREATMENT EMERGENT SEXUAL DYSFUNCTION (TESD) INDUCED BY PRIOR SEROTONIN REUPTAKE INHIBITOR TREATMENT |
EQ 5MG BASE | TRINTELLIX | TAKEDA PHARMS USA | N204447 | Sept. 30, 2013 | RX | TABLET | ORAL | 9278096 | March 21, 2032 | USE IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER TO IMPROVE TREATMENT EMERGENT SEXUAL DYSFUNCTION (TESD) INDUCED BY PRIOR SEROTONIN REUPTAKE INHIBITOR TREATMENT |
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
---|---|---|---|---|---|---|---|---|---|
EQ 10MG BASE | TRINTELLIX | TAKEDA PHARMS USA | N204447 | Sept. 30, 2013 | RX | TABLET | ORAL | Nov. 13, 2023 | INFORMATION ADDED TO THE LABELING REGARDING THE RESULT OF STUDY LUAA21004-402 |
EQ 15MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TRINTELLIX | TAKEDA PHARMS USA | N204447 | Sept. 30, 2013 | DISCN | TABLET | ORAL | Nov. 13, 2023 | INFORMATION ADDED TO THE LABELING REGARDING THE RESULT OF STUDY LUAA21004-402 |
EQ 20MG BASE | TRINTELLIX | TAKEDA PHARMS USA | N204447 | Sept. 30, 2013 | RX | TABLET | ORAL | Nov. 13, 2023 | INFORMATION ADDED TO THE LABELING REGARDING THE RESULT OF STUDY LUAA21004-402 |
EQ 5MG BASE | TRINTELLIX | TAKEDA PHARMS USA | N204447 | Sept. 30, 2013 | RX | TABLET | ORAL | Nov. 13, 2023 | INFORMATION ADDED TO THE LABELING REGARDING THE RESULT OF STUDY LUAA21004-402 |
EQ 10MG BASE | TRINTELLIX | TAKEDA PHARMS USA | N204447 | Sept. 30, 2013 | RX | TABLET | ORAL | Jan. 22, 2024 | ADDITION OF CLINICAL INFORMATION OBTAINED FROM A PEDIATRIC TRIAL TO SECTION 8.4 OF THE LABELING |
EQ 15MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TRINTELLIX | TAKEDA PHARMS USA | N204447 | Sept. 30, 2013 | DISCN | TABLET | ORAL | Jan. 22, 2024 | ADDITION OF CLINICAL INFORMATION OBTAINED FROM A PEDIATRIC TRIAL TO SECTION 8.4 OF THE LABELING |
EQ 20MG BASE | TRINTELLIX | TAKEDA PHARMS USA | N204447 | Sept. 30, 2013 | RX | TABLET | ORAL | Jan. 22, 2024 | ADDITION OF CLINICAL INFORMATION OBTAINED FROM A PEDIATRIC TRIAL TO SECTION 8.4 OF THE LABELING |
EQ 5MG BASE | TRINTELLIX | TAKEDA PHARMS USA | N204447 | Sept. 30, 2013 | RX | TABLET | ORAL | Jan. 22, 2024 | ADDITION OF CLINICAL INFORMATION OBTAINED FROM A PEDIATRIC TRIAL TO SECTION 8.4 OF THE LABELING |
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Sodium-dependent serotonin transporter | Transporter | INHIBITOR | Ki | 8.80 | SCIENTIFIC LITERATURE | SCIENTIFIC LITERATURE | |||
5-hydroxytryptamine receptor 1A | GPCR | AGONIST | Ki | 7.82 | SCIENTIFIC LITERATURE | SCIENTIFIC LITERATURE | |||
5-hydroxytryptamine receptor 7 | GPCR | ANTAGONIST | Ki | 7.72 | SCIENTIFIC LITERATURE | SCIENTIFIC LITERATURE | |||
5-hydroxytryptamine receptor 1B | GPCR | AGONIST | Ki | 7.48 | SCIENTIFIC LITERATURE | SCIENTIFIC LITERATURE | |||
5-hydroxytryptamine receptor 3A | Ion channel | ANTAGONIST | Ki | 8.43 | SCIENTIFIC LITERATURE | SCIENTIFIC LITERATURE | |||
5-hydroxytryptamine receptor 1D | GPCR | ANTAGONIST | Ki | 7.27 | DRUG LABEL | DRUG LABEL | |||
Histamine H2 receptor | GPCR | Ki | 6.74 | CHEMBL | |||||
5-hydroxytryptamine receptor 5A | GPCR | Ki | 6.66 | CHEMBL | |||||
Beta-1 adrenergic receptor | GPCR | Ki | 7.34 | CHEMBL | |||||
Beta-2 adrenergic receptor | GPCR | Ki | 6.25 | CHEMBL | |||||
5-hydroxytryptamine receptor 2A | GPCR | Ki | 6.74 | CHEMBL | |||||
5-hydroxytryptamine receptor 2C | GPCR | Ki | 6.74 | CHEMBL | |||||
5-hydroxytryptamine receptor 6 | GPCR | Ki | 6.48 | CHEMBL | |||||
Histamine H1 receptor | GPCR | Ki | 6.74 | CHEMBL | |||||
Sodium-dependent serotonin transporter | Transporter | IC50 | 8.28 | CHEMBL | |||||
5-hydroxytryptamine receptor 3A | Ion channel | Ki | 6.64 | CHEMBL | |||||
5-hydroxytryptamine receptor 1D | GPCR | ANTAGONIST | IC50 | 5.40 | IUPHAR | ||||
5-hydroxytryptamine receptor 7 | GPCR | Ki | 6.70 | SCIENTIFIC LITERATURE | |||||
Sodium-dependent dopamine transporter | Transporter | IC50 | 6.05 | CHEMBL |
ID | Source |
---|---|
3O2K1S3WQV | UNII |
D10184 | KEGG_DRUG |
1253056-29-9 | SECONDARY_CAS_RN |
960203-27-4 | SECONDARY_CAS_RN |
4032784 | VANDF |
C3661282 | UMLSCUI |
CHEBI:76016 | CHEBI |
CHEMBL2104993 | ChEMBL_ID |
9966051 | PUBCHEM_CID |
DB09068 | DRUGBANK_ID |
CHEMBL2107387 | ChEMBL_ID |
D000078784 | MESH_DESCRIPTOR_UI |
9279 | INN_ID |
7351 | IUPHAR_LIGAND_ID |
1439824 | RXNORM |
206222 | MMSL |
235694 | MMSL |
29689 | MMSL |
d08125 | MMSL |
015226 | NDDF |
015227 | NDDF |
708717008 | SNOMEDCT_US |
712748004 | SNOMEDCT_US |
768282000 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Trintellix | HUMAN PRESCRIPTION DRUG LABEL | 1 | 55154-0256 | TABLET, FILM COATED | 10 mg | ORAL | NDA | 29 sections |
Trintellix | HUMAN PRESCRIPTION DRUG LABEL | 1 | 55154-0256 | TABLET, FILM COATED | 10 mg | ORAL | NDA | 29 sections |
Trintellix | HUMAN PRESCRIPTION DRUG LABEL | 1 | 55154-0256 | TABLET, FILM COATED | 10 mg | ORAL | NDA | 29 sections |
Trintellix | HUMAN PRESCRIPTION DRUG LABEL | 1 | 55154-0256 | TABLET, FILM COATED | 10 mg | ORAL | NDA | 29 sections |
Trintellix | HUMAN PRESCRIPTION DRUG LABEL | 1 | 55154-0257 | TABLET, FILM COATED | 20 mg | ORAL | NDA | 29 sections |
Trintellix | HUMAN PRESCRIPTION DRUG LABEL | 1 | 55154-0257 | TABLET, FILM COATED | 20 mg | ORAL | NDA | 29 sections |
Trintellix | HUMAN PRESCRIPTION DRUG LABEL | 1 | 55154-0257 | TABLET, FILM COATED | 20 mg | ORAL | NDA | 29 sections |
Trintellix | HUMAN PRESCRIPTION DRUG LABEL | 1 | 55154-0257 | TABLET, FILM COATED | 20 mg | ORAL | NDA | 29 sections |
Trintellix | HUMAN PRESCRIPTION DRUG LABEL | 1 | 64764-720 | TABLET, FILM COATED | 5 mg | ORAL | NDA | 31 sections |
Trintellix | HUMAN PRESCRIPTION DRUG LABEL | 1 | 64764-720 | TABLET, FILM COATED | 5 mg | ORAL | NDA | 31 sections |
Trintellix | HUMAN PRESCRIPTION DRUG LABEL | 1 | 64764-730 | TABLET, FILM COATED | 10 mg | ORAL | NDA | 31 sections |
Trintellix | HUMAN PRESCRIPTION DRUG LABEL | 1 | 64764-730 | TABLET, FILM COATED | 10 mg | ORAL | NDA | 31 sections |
Trintellix | HUMAN PRESCRIPTION DRUG LABEL | 1 | 64764-750 | TABLET, FILM COATED | 20 mg | ORAL | NDA | 31 sections |
Trintellix | HUMAN PRESCRIPTION DRUG LABEL | 1 | 64764-750 | TABLET, FILM COATED | 20 mg | ORAL | NDA | 31 sections |
Trintellix | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70518-2642 | TABLET, FILM COATED | 20 mg | ORAL | NDA | 30 sections |
Trintellix | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70518-2642 | TABLET, FILM COATED | 20 mg | ORAL | NDA | 30 sections |